


RADIOLOGÍA



www.elsevier.es/rx

ORIGINAL ARTICLES

Evaluation of pneumatosis intestinalis as a complication of lung transplantation



V. Belloch Ripollés^{a,*}, C.F. Muñoz Núñez^a, A. Fontana Bellorín^b, A. Batista Doménech^a, A. Boukhoubza^a, M. Parra Hernández^a, L. Martí-Bonmatí^a

Received 21 December 2022; accepted 17 January 2023 Available online 17 July 2024

KEYWORDS

Pneumatosis cystoides intestinalis; Pneumoperitoneum; Lung transplantation; Computed tomography

Abstract

Introduction: Pneumatosis intestinalis is a radiological finding characterized by the presence of gas in the bowel wall that is associated with multiple entities. Our aim is to know its incidence in lung transplant patients, its physiopathology and its clinical relevance.

Methods: A search of patients with pneumatosis intestinalis was performed in the database of the Lung Transplant Unit of our hospital. The presence of pneumatosis after transplantation was confirmed in all of them and relevant demographic, clinical and imaging variables were collected to evaluate its association and clinical expression, as well as the therapeutic approach after the findings.

Results: The incidence of pneumatosis intestinalis after lung transplantation in our center was 3.1% (17/546), developing between 9 and 1270 days after transplantation (mean, 198 days; median 68 days). Most of the patients were asymptomatic or with mild symptoms, without any major analytical alterations, and with a cystic and expansive radiological appearance. Pneumoperitoneum was associated in 70% of the patients (12/17). Conservative treatment was chosen in all cases. The mean time to resolution was 389 days.

Conclusion: Pneumatosis intestinalis in lung transplant patients is a rare complication of uncertain origin, which can appear for a very long period of time after transplantation. It has little clinical relevance and can be managed without other diagnostic or therapeutic interventions. © 2023 SERAM. Published by Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, Al training, and similar technologies.

E-mail address: vicentebelloch94@gmail.com (V. Belloch Ripollés).

^a Servicio de Radiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain

^b Unidad de Trasplante Pulmonar, Servicio de Cirugía Torácica, Hospital Universitario y Politécnico La Fe, Valencia, Spain

^{*} Corresponding author.

PALABRAS CLAVE

Neumatosis cistoide intestinal; Neumoperitoneo; Trasplante de pulmón; Tomografía computarizada

Valoración de la neumatosis intestinal como complicación del trasplante pulmonar

Resumen

Introducción: La neumatosis intestinal es un hallazgo radiológico caracterizado por la presencia de gas en la pared del intestino que se asocia a múltiples entidades. Nuestro objetivo es conocer su incidencia en pacientes con trasplante pulmonar, su fisiopatología y su relevancia clínica. Material y métodos: Se realizó una búsqueda de pacientes con neumatosis intestinal en la base de datos de la Unidad de Trasplante Pulmonar de nuestro hospital. En todos ellos se confirmó la presencia de neumatosis intestinal tras el trasplante y se recogieron variables demográficas, clínicas y de imagen relevantes para evaluar su asociación y expresividad clínica, así como la actitud terapéutica tras los hallazgos.

Resultados: La incidencia de neumatosis intestinal postrasplante pulmonar en nuestro centro fue del 3,1% (17/546), desarrollándose entre 9 y 1270 días tras el trasplante (media, 198 días; mediana 68 días). La mayoría de los pacientes estaban asintomáticos o con síntomas leves, sin grandes alteraciones analíticas, y con un aspecto radiológico quístico y expansivo. Asoció neumoperitoneo en un 70% (12/17). Se optó por un tratamiento conservador en todos los casos. El tiempo medio hasta la resolución fue de 389 días.

Conclusión: La neumatosis intestinal en pacientes con trasplante pulmonar es una complicación rara, de origen incierto, que puede aparecer en un periodo de tiempo muy amplio tras el trasplante. Tiene escasa relevancia clínica y puede manejarse sin otras intervenciones diagnósticas ni terapéuticas.

© 2023 SERAM. Publicado por Elsevier España, S.L.U. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares.

Introduction

Pneumatosis intestinalis is a radiological finding characterised by the presence of gas in the wall of the small or large intestine. It is associated with multiple entities, ranging from benign to life-threatening conditions such as ischaemia, intestinal obstruction and necrotising enterocolitis. Benign pneumatosis intestinalis is a rare finding, detected incidentally in imaging tests, usually in immunosuppressed patients with solid organ transplantation, graft-versus-host disease, asthma or COPD or as an endoscopy complication. Its occurrence in adult lung transplant patients has been reported as a benign and conservatively managed entity both in isolated cases^{2–12} and in short series. 13–15

Our objective is to describe the incidence of this complication in lung transplant patients, describe its associations and assess its clinical relevance.

Material and methods

A total of 546 adult lung transplants were performed at our university hospital between January 2011 and October 2022 (141 months). The patients were selected by a search (pneumatosis intestinalis or pneumatosis coli or pneumatosis) in the hospital's Lung Transplant Unit database.

In all patients, the presence of pneumatosis intestinalis (considered as the episode) after transplantation was confirmed in their clinical history, and the following relevant variables were gathered to evaluate association and clinical expression:

- Demographic variables: age, sex, indication and type of transplant (single-lung, double-lung or heart-lung), postsurgical complications (yes/no and which).
- Time from transplant to the episode (days).
- Clinical data at the time of the episode: abdominal signs and symptoms, vital signs (blood pressure, heart rate, O₂ saturation and temperature), signs of rejection (yes/no and which), evidence of pulmonary or gastrointestinal infection, blood tests (white blood cell count, CRP, lactate, bicarbonate, amylase pH), immunosuppressive medication (type and dose) and whether the patient was hospitalised.
- Imaging data: indication for the test, imaging technique used to diagnose pneumatosis, radiological findings (presence and distribution of air), pneumoperitoneum, portal or mesenteric venous pneumatosis, free fluid, pneumobilia, indication for other imaging tests.
- Therapeutic approach: medical treatment, surgical treatment, time to resolution of pneumatosis.

The study was approved by the Research Ethics Committee of the Hospital Universitario y Politécnico La Fe (registration number: 2022-925-1).

Results

Of the 546 lung transplant patients, 17 (3.1%, Fig. 1) with pneumatosis intestinalis were identified. The main clinical and radiological data are presented in Table 1. Of the 17 patients included, 12 were male and 5 female, with a mean age of 51 years (range 21–66 years). The indica-

or outpatient)	. Age, sex	Indication; type of Tx	complications	Time from Tx to PI (days)		Vital signs (BP, HR, O ₂ sat., Temp.)	Laboratory	Signs of rejection ^a		Immunosuppressant medication (drug, dose/24 h and blood levels)	Type and indication of the first test in which PI was diagnosed	-	Distribution of PI in abdomino- pelvic CT scans	Attitude and time to resolution (days)
Outpatient	51, F	Congenital heart disease (VSD) and pulmonary hypertension; cardiopulmonary therapy	IMV re-intubation; tracheostomy; PTN; haemorrhagic CVA		No pain; abdominal distension	BP 145/87 mmHg; HR 87 bpm; O ₂ sat. 99%; Temp. 36.5 °C	Normal	Clinical	No	Methylprednisolone (16 mg); cyclosporine (375 mg; 291.5 ng/mL) MM (1000 mg; 0.8 μg/mL, infratherapeutic)		intestinalis and	Ascending colon	Indication AP CT scan; IC to GS; expectant management, no Qx; /
Inpatient	49, F	Primary ciliary dyskinesia; double-lung Tx	No	875	No pain; physical examination normal	BP 113/74 mmHg; HR 66 bpm; O_2 sat. 96%; Temp. 36.8 °C	Leukocytosis $(12.26\times10^3/\mu L)$ with neutrophilia $(10.42\times10^3/\mu L)$; CRP 160 mg/L	No	Yes, viral pneumonia	Prednisone (10 mg); azathioprine (100 mg); tacrolimus (8 mg; 12.2 ng/mL)	•	Pneumatosis intestinalis, free fluid viral pneumonia	Caecum	No CT scan; IC to DM (Digestive Medicine); domperidone treatment, no Qx; 119 days
Outpatient	39, F	Congenital heart disease (ASD) and PHT; heart and double-lung Tx		118	No pain; abdominal distension	BP 123/83 mmHg; HR 75 bpm, O ₂ sat. 98%, Temp. 36.6 °C	Normal	No	No	Prednisone (10 mg), tacrolimus (16 mg; 11.2 ng/mL); MM (360 mg; 0.7 μ g/mL, infratherapeutic)	Chest CT scan; previous PTE	Pneumatosis intestinalis in hepatic flexure	1	No CT scan, no IC; expectant management no Qx; 136 days
npatient	56, M	UIP-type pulmonary fibrosis + PHT; double-lung Tx	CMV replication; multiple FBS; aspergillus infection	48	No pain; physical examination normal	BP 107/70 mmHg; HR 81 bpm; O_2 sat. 98%; Temp. 35.4 °C;	Normal	No	No	Methylprednisolone (20 mg); tacrolimus (4 mg; 10.1 ng/mL); MM (3000 mg; 3 µg/mL)	Chest CT scan; assessment of transplant status	Pneumatosis intestinalis in hepatic flexure	/	No CT scan, no IC; expectant management no Qx; 154 days
Outpatient	39, M	Cystic fibrosis; double-lung Tx	No	1270	No pain; physical examination normal	1	Normal	No	No	Prednisone (10 mg), tacrolimus (3 mg; 7.3 ng/mL); everolimus (3 mg; 8.8 ng/mL)	Chest CT scan; suspected bronchiolitis obliterans syndrome	Pneumatosis intestinalis hepatic flexure and pneumoperi- toneum	/	No CT scan, no IC; expectant management no Qx; 1379 days
npatient	21, M	Cystic fibrosis; double-lung Tx	Prolonged IMV; left-side phrenic nerve paralysis; PEG due to gastroparesis	68	No pain; abdominal distension	BP 128/94 mmHg; HR 104 bpm; O_2 sat. 96% Temp. 36 °C	CRP 48.7 mg/L	Clinical	No	Methylprednisolone (20 mg); tacrolimus (5 mg; 8.5 ng/mL); MM (1500 mg; 3.4 μg/mL)	Chest CT scan; assess atelectasis detected on X-ray	Pneumatosis intestinalis	/	No CT scan, no IC; expectant management no Qx; 105 days
npatient	40, M	Pneumoconiosis (silicosis); right-sided one-lung Tx	No	64	No pain; physical examination normal	BP 97/57 mmHg; HR 86 bpm; O_2 sat. Temp. 36.7 $^{\circ}$ C	$(17.47 \times 10^3/\mu L)$	Clinical	Yes, cough and pleural effusion	Methylprednisolone (40 mg); tacrolimus (3 mg; 23 ng/mL, overdosage); MM (1000 mg; 3.4 µg/mL)	CT scan; desaturation,	Pneumatosis intestinalis and pneumoperi- toneum	colon and hepatic	Indication AP CT scan; IC to GS; expectant management no Qx; 215 days

Patient (inpatien or outpatient)	t Age, sex	Indication; type of Tx	Postoperative complications	Time from Tx to PI (days)	Symptoms; signs	Vital signs (BP, HR, Laboratory O ₂ sat., Temp.)	Signs of rejection ^a		Immunosuppressant medication (drug, dose/24 h and blood levels)	Type and indication of the first test in which PI was diagnosed	Radiological findings	Distribution of PI in abdomino- pelvic CT scans	Attitude and time to resolution (days)
3 Outpatient	58, M	Emphysema-type COPD; double-lung Tx	Bronchial stenosis; persistent air leak; multiple FBS	169	Vomiting, increased stool rhythm; physical examination normal	BP 136/66 mmHg; Normal HR 67 bpm; O ₂ sat. 98%; Temp. 36.2 °C	No	No	Prednisone (5 mg); tacrolimus (2 mg; 10.9 ng/mL); MM (1000 mg; 0.9 μg/mL)	Chest CT scan; assess airway stenosis	Pneumatosis intestinalis and pneumoperi- toneum	Caecum, ascending colon, hepatic flexure, transverse, splenic flexure,	Indication AP CT scan; IC to DGM; expectant management, no Qx; indication CT scan in 1–3 months; 75 days
Outpatient	61, M	UIP-type pulmonary fibrosis; right-lung Tx	No	38	No pain; physical examination normal	BP 115/66 mmHg; Normal HR 75 bpm; O ₂ sat. 97%	Biopsy: acute cellular rejection (A1—2) and inflammatory bronchiolitis (B1R)		Methylprednisolone (16 mg); tacrolimus (3 mg; 15.6 ng/mL); MM (3000 mg; 3.1 μg/mL)	Chest X-ray; assessment of transplant status	Hepatic and splenic flexure pneumatosis and pneumoperi- toneum	Pneumatosis resolved at time of CT scan	Indication AP CT scan; no IC; expectant management, no Qx; 1591 days
O Outpatient	47, M	Pulmonary fibrosis, double-lung Tx	Tracheostomy; prolonged IMV; right phrenic nerve paralysis	149	No pain; physical examination normal	BP 115/77 mmHg; Normal HR 73 bpm; $\rm O_2$ sat. 96%; Temp. 36.6 $^{\circ}$ C	No	No	Prednisone (10 mg); tacrolimus (4 mg; 11.1 ng/mL); MM (2000 mg; 1.1 μg/mL)	Chest CT scan; functional respiratory impairment	Pneumatosis intestinalis and pneumoperi- toneum	colon and hepatic	Indication AP CT scan; no IC; expectant management, no Qx; 368 days
1 Inpatient	63, M	UIP type pulmonary fibrosis; double-lung Tx	Haemothorax; post-surgical ECMO; tracheostomy; heart failure	68	No pain; physical examination normal	BP 125/82 mmHg; PCR 17 mg/L HR 91 bpm; O $_2$ sat. 95%; Temp. 36.1 $^{\circ}\text{C}$	No	No	Methylprednisolone (8 mg); tacrolimus (4 mg; 10.6 ng/mL); MM (500 mg; 0.7 µg/mL infratherapeutic)	Chest CT scan; recurrent pleural effusion with signs of organisation		and transverse	Indication AP CT scan; no HF; expectant management, no Qx; 73 days
2 Inpatient	63, F	UIP type pulmonary fibrosis; double-lung Tx	Gastroparesis	27	Nausea, diarrhoea, gastropare- sis, bloated abdomen, discomfort on deep epigastric palpation	BP 125/81 mmHg; Normal HR 80 bpm; O ₂ sat. 94%; Temp. 36.1 °C	Biopsy: no signs of acute cellular rejection (A0) and inflammatory bronchiolitis (B1R)	one vomiting and diarrhoea	Methylprednisolone (40 mg); tacrolimus (16 mg; 17.4 ng/mL, supratherapeutic); MM (2000 mg; 1.9 μg/mL)	Chest CT scan; assess sternal suture	Pneumatosis intestinalis and pneumoperi- toneum	Terminal ileum, caecum, ascending and transverse colon	Indication AP CT scan; IC to DGM; domperidone Tt., no Qx; /

or outpatient)	Age, sex	Indication; type of Tx	Postoperative complications	Time from Tx to PI (days)		Vital signs (BP, HR, O ₂ sat., Temp.)	·	Signs of rejection ^a		Immunosuppressant medication (drug, dose/24 h and blood levels)	first test in which PI was diagnosed	Radiological findings	Distribution of PI in abdomino- pelvic CT scans	Attitude and time to resolution (days)
Inpatient	66, M	Idiopathic pulmonary fibrosis; left single-lung Tx	No	20	No pain; physical examination normal	BP 145/72 mmHg; HR 83 bpm; O ₂ sat. 99%; Temp. 36.4 °C	Normal	Clinical	No	Methylprednisolone (20 mg); tacrolimus (6.5 mg; 8.9 ng/mL, infratherapeutic); MM (3000 mg; 4.2 μg/mL)	Chest CT scan; rule out thoracotomy dehiscence	Pneumatosis intestinalis ascending colon, hepatic flexure and transverse and pneumoperi- toneum	7	No CT scan, no IC; expectant management, no Qx; 72 days
Inpatient	24, F	Cystic fibrosis; double-lung Tx	Wound infection		Right flank pain, diarrhoea; guarding on examination right flank, no peritoneal irritation	HR 112 bpm; O₂ sat. 100%; Temp. 37 °C;	Leukocytosis (21.30 \times 10 3 / μ L) with neutrophilia (19.52 \times 10 3 / μ L); CRP 381 mg/L; procalcitonin 18.32 ng/L; lactate 1.8 mmol/L; HCO3 2 21.5 mmol/L; pH 7.39	Clinical	C. difficile pancolitis	Prednisone (30 mg); tacrolimus (5 mg; 6.6 ng/mL, infratherapeutic); MM (3000 mg; 1.6 μ g/mL)	CT scan; Clinical and analytical deterioration in a	Pneumatosis intestinalis, portal pneumatosis, free fluid, wall thickening colon: <i>C. difficile</i> pancolitis	ascending colon,	IC to GS; antibiotic Tmt. with fidaxomicin, no Qx. Dx C. difficile pancolitis; 3 days
5 Inpatient	63, M	Emphysema type COPD; right single-lung Tx	Lithium poisoning		No pain, abdominal discomfort with ingestion; physical examination normal	BP 115/82 mmHg; HR 103 bpm; O_2 sat. 99%; Temp. 35.4 $^{\circ}$ C		Clinical	No	Methylprednisolone (40 mg); tacrolimus (4 mg; 17.4 ng/mL, supratherapeutic); MM (540 mg; 7.6 μg/mL, supratherapeutic)	Chest CT scan; assessment of transplant status	Pneumatosis intestinalis and pneumoperi- toneum	Caecum, ascending colon	Indication AP CT scan; IC to DGM and GS; expectant management, no Qx; 384 days

										levels)	PI was diagnosed		pelvic CT	(days)
16 Inpatient	62, M	Emphysema-type COPD; double-lung Tx	Air leak; thoracotomy and sternotomy surgical dehiscence	9	Subcutaneous emphysema	BP 126/60 mmHg; HR 86 bpm; O₂ sat. 95%; Temp. 37 °C	Leukocytosis $(15\times 10^3/\mu L)$ with neutrophilia $(12.77\times 10^3/\mu L);$ CRP 27.5 mg/L	No	No	Methylprednisolone (60 mg); tacrolimus (6 mg; 12.1 ng/mL); MM (1000 mg; 7.5 µg/mL, supratherapeutic)	Chest CT scan; assessment of transplant status	Gastric pneumatosis and pneumoperi- toneum. Bilateral pneumotho- rax, subcutaneous	scans /	No CT scan; IC to DGM; surgical Trt. for air leak and surgical dehiscence; 22 days
17 Inpatient	63, M	Emphysema-type COPD; double-lung Tx	No	14	No pain; physical examination normal	BP 122/85 mmHg; HR 88 bpm; O_2 sat. 100%; Temp. 36 °C	Leukocytosis $(13\times10^3~\mu/L)$ with neutrophilia $(11\times10^3~\mu/L);$ CRP 7.6 mg/L	No	No	Methylprednisolone (50 mg); tacrolimus (10 mg; 11.1 ng/mL); MM (3000 mg; 2.7 µg/mL, supratherapeutic)	Chest CT scan; assessment of transplant status	emphysema Pneumatosis intestinalis ascending colon, hepatic flexure, transverse, splenic flexure and descending	/	No CT scan; IC to DGM; expectant management, no Qx; /

Signs of

rejectiona

Signs of

Type and

indication of the findings

and pneumoperi-

Immunosuppressant

GI infection dose/24 h and blood first test in which

pulmonary or medication (drug,

Radiological Distribution Attitude and

abdomino-

time to

resolution

of PI in

Time from Tx Symptoms; Vital signs (BP, HR, Laboratory

O₂ sat., Temp.)

to PI (days) signs

complications

(Continued)

Patient (inpatient Age, sex Indication; type Postoperative

of Tx

Table 1

319

or outpatient)

AP CT: abdomino-pelvic CT scan; ASD: atrial septal defect; BP: blood pressure; CMV: cytomegalovirus; COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident; DGM: digestive medicine; Dx: diagnosis; ECMO: extracorporeal membrane oxygenation; F: female; FBS: fibrobronchoscopy; GI: gastrointestinal; GS: general surgery; HCO3⁻: bicarbonate; HR: heart rate; IC: interconsultation; IMV: invasive mechanical ventilation; M: male; MM: mycophenolate mofetil; NIVM: non-invasive mechanical ventilation; O₂ sat.: oxygen saturation; PEG: percutaneous endoscopic gastrostomy; PI: pneumatosis intestinalis; PHT: pulmonary hypertension; PTN: parenteral nutrition; PTE: pulmonary thromboembolism; Qx: surgery; Rx: X-ray; Temp.: temperature; Tmt: treatment; Tx: transplantation; UIP: usual interstitial pneumonia; VSD: ventricular septal defect.

^a Signs of rejection: defined as the occurrence of any clinical or pathological event that resulted in the application of high-dose steroid boluses. Pathological classification of pulmonary rejection of the International Society for Heart and Lung Transplantation (ISHLT).¹⁷




Figure 1 Screening diagram and reasons for the exclusion of patients included in the series.

tions for transplantation were pulmonary fibrosis (6 cases), emphysema (4 cases), cystic fibrosis (3 cases), congenital heart disease with pulmonary hypertension (2 cases), primary ciliary dyskinesia (1 case) and pneumoconiosis (1 case). Transplantation was either single-lung (n = 4), doublelung (n = 11) or heart-double lung (n = 2). Some type of post-surgical complication was observed in 11 patients with pneumatosis (65%).

The mean time from transplantation to diagnosis was 198 days and the median was 68 days, ranging from 9 to 1270 days. When pneumatosis was diagnosed, 16 patients (94%) were asymptomatic or had mild abdominal discomfort (n = 2), bloating (n = 3), nausea/vomiting (n = 2) or diarrhoea (n = 1). In this group, the physical examination was normal. Only 6 patients had leukocytosis with neutrophilia and elevated CRP (Table 1). The symptomatic patient (no. 14 in Table 1) was diagnosed with *Clostridium difficile* (*C. difficile*) colitis.

At the time of the episode, 8 patients had clinical or pathological signs of rejection (47%) and 4 had signs of pulmonary (n=2) or gastrointestinal (n=2) infection. Eleven patients were inpatients (65%) and 6 were outpatients. All patients were on immunosuppressive treatment (corticosteroids, calcineurin inhibitors and antiproliferative agents).

In 76% of the cases (n = 13) pneumatosis was identified on the chest X-ray or CT scan, whose most frequent indication was to assess lung transplantation status (Fig. 2). The remaining cases were diagnosed by an abdomino-pelvic CT scan. Pneumatosis was most frequently observed in the ascending colon, hepatic flexure and transverse colon. The pneumatosis involved the caecum (n = 5), ascending colon (n = 10), hepatic flexure (n = 10), transverse colon (n = 7), splenic flexure (n = 3), descending colon (n = 2), sigmoid colon (n = 1), rectum (n = 1), terminal ileum (n = 1) and gastric fundus (n = 1). However, only 10 patients (59%) had an abdomino-pelvic CT scan to assess the distribution of pneumatosis throughout the bowel (Table 1). The patient with gastric pneumatosis (no. 16) also had a bilateral pneumothorax, multiple small breaks in continuity in the chest wall, both in the thoracotomy and sternotomy

sutures, subcutaneous emphysema, and was diagnosed with air leak with thoracotomy dehiscence as a post-surgical complication.

The findings associated with pneumatosis observed were pneumoperitoneum in 12 patients (70%), free fluid in 2 cases (12%) and portal venous pneumatosis in 1 case (6%). No mesenteric venous pneumatosis or pneumobilia was identified in any case. One of the patients with free fluid (no. 14) was diagnosed with Clostridium colitis. Finally, 10 interconsultations were made to the Digestive Medicine (n = 6) and Digestive Surgery (n = 4) departments for the evaluation of 9 patients, 8 of whom were asymptomatic. Forty-six per cent (46%) of the patients diagnosed by chest radiography or CT scan (6/13) had an abdomino-pelvic CT scan to complete the study. Treatment was expectant management in all the cases of asymptomatic pneumatosis intestinalis. The patient with colitis (no. 14) was treated with antibiotics and the patient with gastric pneumatosis and air leak (no. 16) underwent surgery.

The mean time to resolution was 389 days (median 145 days, range 72-1591 days).

Discussion

The incidence of post-lung transplantation pneumatosis intestinalis in our hospital was 3.1%, occurring between 9 and 1270 days post-transplantation. Patients were asymptomatic or with mild symptoms, with no major laboratory abnormalities. The radiological appearance was cystic/expansive. Treatment was conservative in all asymptomatic cases.

Of the 55 published cases of pneumatosis intestinalis in lung transplant patients, 15 were clinical cases $^{2-12}$ and 40 in series of 7, 13 10 14 and 23 15 patients. The incidence published by Thompson et al. (2%), 13 Chandola et al. (2.68%) 14 and Christiansen et al. (5.2%) 15 is similar to our own. Since it is often an incidental finding, the true incidence is probably being underestimated. The time from transplantation to onset in the series of Thompson et al. (median 105 days,




Figure 2 58-year-old male with incidental finding of pneumatosis intestinalis and pneumoperitoneum under study for evaluation of lung transplantation (patient no. 8). Coronal reconstructions A and B) and transverse sections C and D) in lung window A and C) and soft tissue window B and D) of thoracic CT scan without intravenous contrast. A and B) Lung grafts without significant alterations. C and D) Extensive pneumatosis intestinalis is observed in the hepatic and splenic flexures of the colon (arrows), with localised air bubbles in the submucosa and serosa of the colon walls dissecting mesenteric fatty planes and delimiting the posterior aspect of the parietal peritoneum in the left hypochondrium (arrowheads). The study was completed with a contrast-enhanced abdomino-pelvic CT scan shown in Fig. 4.

range 18–453 days), ¹³ Chandola et al. (median 82 days, range 5–2495 days) ¹⁴ and Christiansen et al. (median 47 days, range 5–1477 days) ¹⁵ is similar to our own (median 68 days, range 9–1270 days). Although this is a complication that may occur over a long period of time, it is eminently late, usually appearing 6 months after the transplantation. As in the previous series, ^{13–15} most patients were asymptomatic or had mild abdominal symptoms, with no major abnormalities on physical examination or in the laboratory tests. Patients who were truly symptomatic or had other associated disorders had alternative diagnoses to benign pneumatosis intestinalis.

Benign pneumatosis intestinalis in transplantees often has a cystic and expansive appearance (Fig. 3), with a large amount of air in the intestinal wall. It is useful to evaluate it with the lung window to ascertain the extent (Fig. 4). In contrast, pneumatosis intestinalis due to intestinal ischaemia or occlusion predominantly affects the small bowel, and the gas bubbles usually present a finer and more linear arrangement in the wall¹⁵ and are accompanied by other warning signs such as wall thickening or thinning, absence of mural enhancement, dilatation of the intestinal loops,

free fluid and inflammatory changes in the adjacent mesentery (Fig. 5). This expansive aspect of pneumatosis and the absence of other radiological findings support a benign aetiology and clinical course. ¹⁵

In our series, pneumatosis intestinalis was associated with pneumoperitoneum, portomesenteric gas and free fluid. Seventy percent of the patients in our series had associated pneumoperitoneum dissecting mesenteric fatty planes. Only one of these patients underwent surgery for an air leak with dehiscence of the sternothoracotomy (no. 16). Portal venous gas has been linked to an increased risk of requiring surgery. ¹³ In our series, the only diagnosed case of *C. difficile* pancolitis was associated with free fluid and colon wall thickening.

The pathophysiology of pneumatosis intestinalis in transplant recipients remains unclear. Three causal mechanisms have been proposed: mechanical, bacteriological and biochemical. The mechanical theory suggests that gas dissects into the intestinal wall from the intestinal lumen or the mediastinum due to increased intraluminal or mediastinal pressure, as occurs in mechanically ventilated patients swith asthma or COPD. In our series, there were no patients




Figure 3 63-year-old woman with double-lung transplant for UIP-type fibrosis (patient no. 12). Abdominal CT scan with intravenous contrast performed after an incidental finding of colonic pneumatosis and pneumoperitoneum on thoracic CT scan performed to assess the sternal suture. Transverse sections in soft tissue window A) and lung B) and coronal reconstructions with soft tissue window C) and lung D). Cystic pneumatosis intestinalis in the caecum, ascending and transverse colon, with expansive appearance and a large amount of air (arrows). Abundant pneumoperitoneum both right subdiaphragmatic and in the form of large bubbles dissecting the mesenteric fat (asterisks).




Figure 4 Same patient as in Fig. 2. 58-year-old male with an incidental finding of pneumatosis intestinalis and pneumoperitoneum after lung transplantation (patient no. 8). A) Computed tomography topogram showing extensive pneumatosis intestinalis (arrowheads). Coronal reconstruction of computed tomography with intravenous contrast in soft tissue window B) and lung window C). B) The soft tissue window permits the evaluation of radiological findings associated with ectopic air, such as assessing correct uptake of the loops (arrow) and the absence of intra-abdominal free fluid. C) The lung window makes it possible to locate and assess the extent of both the pneumatosis intestinalis, extending in this case along the entire colic frame from the caecum to the sigma (arrowheads), and the pneumoperitoneum, which has a cystic and expansive appearance, dissecting mesenteric fatty planes (asterisk).




Figure 5 Example of pneumatosis intestinalis and pneumoperitoneum due to acute mesenteric ischaemia. Cross-sectional images of venous phase intravenous contrast-enhanced computed tomography with soft tissue window A) and lung window B); and sagittal reconstruction of study performed in arterial phase C). A) Dilated, thin-walled, non-enhanced small bowel loops (white arrowheads in A and C), with free fluid (asterisk in A and C) and associated mesenteric venous pneumatosis (arrows in A-C). B) Pneumatosis intestinalis (black arrowheads) and pneumoperitoneum (dashed arrow). C) Critical stenosis of the superior mesenteric artery at its origin (hollow arrow).

on mechanical ventilation during the episode. On the other hand, gas-producing bacteria enter the submucosa through defects in the mucosa and produce gas in the intestinal wall. 16 Some publications have attributed pneumatosis intestinalis to CMV^{9,10} or *C. difficile*¹¹ infections, which are common in the context of immunosuppression and are inevitably associated with transplantation. In our series, no patient presented active CMV infection and only one patient presented Clostridium colitis, whose clinical-radiological appearance was different from the asymptomatic cases. The biochemical theory¹⁶ postulates that excessive fermentation of carbohydrates in the intestinal lumen by bacteria produces gas, which is absorbed by the intestinal wall. The cystic presentation of pneumatosis in transplant patients is not conducive to this being the causative mechanism.

The association of pneumatosis with atrophy of lymphoid tissues in the intestinal wall due to immunosuppression related to the intake of immunosuppressants and corticosteroids in transplant recipients has been described. ¹⁵ This atrophy compromises mucosal integrity and allows gas to enter the intestinal wall. The use of immunosuppressants and corticosteroids is an antecedent that is present in all patients in the published series ^{13–15} and in our own, hence it

would be reasonable for it to have a relevant role in the pathophysiology of post-transplant pneumatosis, probably propitiating the mechanism described by the mechanical theory. Christiansen et al. ¹⁵ relate the development of pneumatosis to the placement of gastrojejunostomy tubes. In our series, post-transplantation nutrition was mainly oral, or parenteral when the latter was not possible; only one case (no. 6) had a gastrostomy at the time of the diagnosis of pneumatosis.

Although further complementary tests and consultations are often requested, the therapeutic decision was conservative in all cases. There are cases described in the literature^{5,13,15} of exploratory laparotomies due to radiological findings, despite the absence of symptoms and a normal physical examination and blood tests. In the series of Christiansen et al.,¹⁵ these patients are treated with supplemental oxygen, bowel rest and antibiotics, without altering the immunosuppressive regimen. In the majority of cases in our hospital, a watchful waiting attitude was maintained, without any therapeutic modification, and only in two cases was domperidone prescribed as a prokinetic (numbers 2 and 12), with a good clinical evolution in all cases and an average time to resolution of 389 days. Medical treatment should be symptomatic, and the addition

of antimicrobial treatment is debatable in the absence of infectious symptoms. Finally, verifying resolution does not seem to be necessary, since it may take time to disappear or it may present a relapsing-remitting evolution, in most cases following a benign clinical course with conservative management.

Some of this study's limitations are that it is a retrospective series, with the possibility of unrecorded or undetected cases or with an alternative, unidentified origin of the pneumatosis. Future prospective studies would permit a more precise determination of the incidence and time to onset and resolution of this entity.

Conclusions

Pneumatosis intestinalis in lung transplant recipients is a rare complication of uncertain origin that can occur over a long period of time after transplantation. It has a characteristic radiological presentation of cystic/expansive appearance, which may or may not be associated with pneumoperitoneum and, in the absence of symptoms or other associated alterations, is of scant clinical relevance and can be managed without further diagnostic or therapeutic interventions.

Authorship/collaborators

- Responsible for the integrity of the study: Vicente Belloch Ripollés, Carlos Francisco Muñoz Núñez, Luis Martí-Bonmatí.
- 2. Study conception: Vicente Belloch Ripollés, Carlos Francisco Muñoz Núñez.
- Study design: Vicente Belloch Ripollés, Carlos Francisco Muñoz Núñez.
- Data collection: Vicente Belloch Ripollés, Alilis Fontana Bellorín, Ali Boukhoubza, María Parra Hernández.
- Data analysis and interpretation: Vicente Belloch Ripollés, Carlos Francisco Muñoz Núñez, Alilis Fontana Bellorín.
- 6. Statistical processing: Vicente Belloch Ripollés.
- 7. Bibliographic search: Vicente Belloch Ripollés, Ali Boukhoubza, María Parra Hernández.
- 8. Editorial staff: Vicente Belloch Ripollés, Luis Martí-Bonmatí.
- Critical review of the manuscript with intellectually relevant contributions: Carlos Francisco Muñoz Núñez, Alilis Fontana Bellorín, Adela Batista Doménech, Luis Martí-Bonmatí.
- Approval of the final version: Vicente Belloch Ripollés, Carlos Francisco Muñoz Núñez, Alilis Fontana Bellorín, Adela Batista Doménech, Ali Boukhoubza; María Parra Hernández, Luis Martí-Bonmatí.

Conflicts of interest

The authors declare that they have no conflicts of interest.

References

- 1. Khalil PN, Huber-Wagner S, Ladurner R, Kleespies A, Siebeck M, Mutschler W, et al. Natural history, clinical pattern, and surgical considerations of pneumatosis intestinalis. Eur J Med. 2009;14:231-9, http://dx.doi.org/10.1186/2047-783X-14-6-231.
- Ling FY, Zafar AM, Angel LF, Mumbower AL. Benign pneumatosis intestinalis after bilateral lung transplantation. BMJ Case Rep. 2015, http://dx.doi.org/10.1136/bcr-2015-210701, 2015:bcr2015210701.
- 3. Chen WL, Zhao L, Guo LJ, Liang CY, Chen JY, Chen WH. Pneumatosis cystoides intestinalis in lung transplant recipients: three cases report and literature review. Chin J Tuberc Respir Dis. 2022;45:671–6, http://dx.doi.org/10.3760/cma.j.cn112147-20220106-00022.
- Otsuka S, Ujiie H, Kato T, Shiiya H, Fujiwara-Kuroda A, Hida Y, et al. Pneumatosis intestinalis after living donor lung transplantation associated with alpha-glucosidase inhibitor treatment: a case report. Transplant Proc. 2021;53:1379–81, http://dx.doi.org/10.1016/j.transproceed.2021.02.006.
- Beetz O, Kleine M, Vondran FWR, Cammann S, Klempnauer J, Kettler B. A case of recurrent pneumoperitoneum and pneumatosis intestinalis after bilateral lung transplant. Exp Clin Transplant Off J Middle East Soc Organ Transplant. 2019;17:124-7, http://dx.doi.org/10.6002/ect.2016.0249.
- Ho LM, Mosca PJ, Thompson WM. Pneumatosis intestinalis after lung transplant. Abdom Imaging. 2005;30:598-600, http://dx.doi.org/10.1007/s00261-005-0311-y.
- 7. Mesaki K, Sugimoto S, Otani S, Kurosaki T, Miyoshi K, Yamane M, et al. Pneumatosis intestinalis after lung transplantation for pulmonary graft-versus-host disease. J Thorac Dis. 2018;10:E42–5, http://dx.doi.org/10.21037/jtd.2017.11.121.
- Chandola R, Elhenawy A, Lien D, Laing B. Massive gas under diaphragm after lung transplantation: pneumatosis intestinalis simulating bowel perforation. Ann Thorac Surg. 2015;99:687–9, http://dx.doi.org/10.1016/j.athoracsur.2014.03.047.
- Mannes GP, de Boer WJ, van der Jagt EJ, Meinesz AF, Meuzelaar JJ, van der Bij W. Pneumatosis intestinalis and active cytomegaloviral infection after lung transplantation. Groningen Lung Transplant Group. Chest. 1994;105:929–30, http://dx.doi.org/10.1378/chest.105.3.929.
- Böhler A, Speich R, Russi EW, Meyenberger C, Weder W. Pneumatosis intestinalis and active cytomegaloviral infection after lung transplantation. Chest. 1995;107:582-3, http://dx.doi.org/10.1378/chest.107.2.582.
- 11. Schenk P, Madl C, Kramer L, Ratheiser K, Kranz A, Zauner C, et al. Pneumatosis intestinalis with Clostridium difficile colitis as a cause of acute abdomen after lung transplantation. Dig Dis Sci. 1998;43:2455–8, http://dx.doi.org/10.1023/a:1026682131847.
- 12. Van Den Bosch J, Broos P, Vijgen G. Is surgical exploration necessary in asymptomatic intestinal pneumatosis after lung transplantation? BMJ Case Rep. 2021;14:e243955, http://dx.doi.org/10.1136/bcr-2021-243955.
- 13. Thompson WM, Ho L, Marroquin C. Pneumatosis intestinalis and pneumoperitoneum after bilateral lung transplantation in adults. AJR Am J Roentgenol. 2011;196:W273-9, http://dx.doi.org/10.2214/AJR.10.4468.
- 14. Chandola R, Laing B, Lien D, Mullen J. Pneumatosis intestinalis and its association with lung transplant: Alberta experience. Exp Clin Transplant. 2018;16:75–80, http://dx.doi.org/10.6002/ect.2016.0289.
- 15. Christiansen E, Singh N, Trahan A, Tokman S, Row D, Kalinkin O. Pneumatosis intestinalis in adult bilateral lung

- transplant patients: a single institution experience and literature review. Case Rep Transplant. 2020;2020:5023948, http://dx.doi.org/10.1155/2020/5023948.
- **16.** Heng Y, Schuffler MD, Haggitt RC, Rohrmann CA. Pneumatosis intestinalis: a review. Am J Gastroenterol. 1995;90:1747–58.
- 17. Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, et al. Revision of the 1996 working formula-

tion for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2007;26:1229-42, http://dx.doi.org/10.1016/j.healun.2007.10.017.